|View printer-friendly version|
The conversion value of any Series A Notes converted on or after today will be determined based on the volume-weighted average price of
The current conversion rate for the Series A Notes is 187.6877 shares of
Holders of the Series A Notes may convert their notes at any time prior to close of business on the business day immediately preceding February 1, 2018.
Capitalized terms used but not defined in this press release have the respective meanings set forth in the Series A Indenture.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy the Series A Notes, the 2018 Notes,
Safe Harbor Statement
Statements made in this press release that are not statements of historical fact are forward-looking statements and are subject to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release relate, but are not limited, to the settlement or repayment of the Series A Notes and the 2018 Notes. These forward-looking statements involve risks and uncertainties. If any of these risks or uncertainties materialize, or if any of the Company's assumptions prove incorrect, actual results could differ materially from the results expressed or implied by these forward-looking statements. These risks and uncertainties include, but are not limited to,
Forward-looking statements speak only as of the date the statements are made and are based on information available to
Investor Relations, EVC Group
+1 (415) 652-9100
+1 (408) 789-4426
View original content with multimedia:http://www.prnewswire.com/news-releases/accuray-elects-net-share-settlement-for-350-series-a-convertible-senior-notes-due-2018-300577185.html
© 2007 - 2016 Accuray Incorporated. All Rights Reserved. Accuray, the stylized logo, CyberKnife, TomoTherapy, Synchrony, Xsight, Xchange, TomoHD, Hi-Art, and RoboCouch are among the trademarks and / or registered trademarks of Accuray Incorporated in the United States and other countries.
Important Safety Information: Most side effects of radiotherapy, including radiotherapy delivered with Accuray systems, are mild and temporary, often involving fatigue, nausea, and skin irritation. Side effects can be severe, however, leading to pain, alterations in normal body functions (for example, urinary or salivary function), deterioration of quality of life, permanent injury and even death.
Side effects can occur during or shortly after radiation treatment or in the months and years following radiation. The nature and severity of side effects depend on many factors, including the size and location of the treated tumor, the treatment technique (for example, the radiation dose), the patient's general medical condition, to name a few. For more details about the side effects of your radiation therapy, and if treatment with an Accuray product is right for you, ask your doctor.